Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET bispecific "avelumab" has received approval for a new indication in China.

According to the Wise Financial APP, on August 8, Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET dual antibody "Amivantamab" has been approved for a new indication in China. It is approved for use in combination with lazertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.